Perspectiva jurídica frente a la aplicación del Régimen de nulidades absolutas del Estatuto general de contratación pública en los contratos de concesión o de APP

Al margen, de lo ordenado por la Corte Constitucional en Sentencia C- 207 de 2019, mediante la cual, aplicó el artículo 1525 del Código Civil para negar cualquier tipo de reconocimiento en la liquidación de un contrato de concesión o de APP que adolezca de alguna nulidad absoluta, a quienes hayan actuado a sabiendas del objeto o la causa ilícita; el presente trabajo tiene como propósito sustentar una reflexión jurídica, académica, respecto de la prevalencia de la aplicación del régimen jurídico de nulidades absolutas en la contratación estatal, definido desde la Ley 80 de 1993 y la Ley 1882 de 2018, cuando se declare nulo o se termine por una causal de nulidad un contrato de concesión o de APP; con el objeto de garantizar el reconocimiento de todas las acreencias del proyecto hasta la declaratoria de la nulidad, siempre que se haya beneficiado la entidad y hasta el monto de dicho beneficio. Palabras clave: régimen de nulidades en la contratación estatal, nulidades absolutas, contratación estatal, contrato de concesión, contrato de asociación público privada –APP-, artículo 1525 del Código Civil.The purpose of this master’s thesis is to do a legal and academic analysis narrowly focused on the application of the void contract theory in public contracts pursuant to “Ley 80 de 1993" and “Ley 1882 de 2018", how to declare or terminate concession or APP contracts for voidable reasons, and the economic obligations that arise from the termination, as long as the entity has benefited from the performance of the contract, and capped by the benefit. I will also explore the effects of the Constitutional Court decision “C- 207 de 2019", where the Court applied Civil Code section 1525 and held that there will be no compensation in concession or APP contracts, when the contract is declared void because the subject matter is illegal and the parties knew about it at the time of the contract formation. Key words: Application of the void contract theory in public contracts, concession contract, PPP contract, Section 1525 of the Civil Code.Magíster en Derecho AdministrativoMaestrí

El principio de la confianza legítima para establecer una contratación pública eficiente

Dentro del proceso de selección objetiva en la licitación pública se presentan deficiencias importantes en la elaboración del pliego de condiciones y en la evaluación de las ofertas por parte de la Administración, que inciden negativamente en la condición de proponente que espera que los requerimientos que conoció en el pliego de condiciones no sean abruptamente cambiados por la entidad.In the process of objective selection process in a public bidding there are important deficiencies in the process of making the terms and conditions of the public bidding and during the bid evaluation by the administration, that affect in a negative way the conditions of the une who offers that expects that the requirements that were known previously in the terms and conditions of the public bidding won t be changed by the administration.Abogado (a)Pregrad

Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

Background: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing comorbidities, vital signs, chronic and acute treatments, complications, dates of hospitalization and discharge, mortality, viral strains, vaccination status, and other data. Here, we present the dataset characteristics, explain its architecture and how to gain access, and provide tools to facilitate its use

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death

The value of open-source clinical science in pandemic response: lessons from ISARIC

International audienc